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Abstract
Background: Biomarkers of disease progression in amyotrophic lateral sclerosis (ALS) could support the identification of
beneficial drugs in clinical trials. We aimed to test whether soluble fragments of beta-amyloid precursor protein (sAPPa and
sAPPß) correlated with clinical subtypes of ALS and were of prognostic value.
Methodology/Principal Findings: In a cross-sectional study including patients with ALS (N= 68) with clinical follow-up data
over 6 months, Parkinson’s disease (PD, N= 20), and age-matched controls (N = 40), cerebrospinal fluid (CSF) levels of sAPPa
a, sAPPß and neurofilaments (NfHSMI35) were measured by multiplex assay, Progranulin by ELISA. CSF sAPPa and sAPPß
levels were lower in ALS with a rapidly-progressive disease course (p = 0.03, and p= 0.02) and with longer disease duration
(p = 0.01 and p= 0.01, respectively). CSF NfHSMI35 was elevated in ALS compared to PD and controls, with highest
concentrations found in patients with rapid disease progression (p,0.01). High CSF NfHSMI3 was linked to low CSF sAPPa
and sAPPß (p = 0.001, and p= 0.007, respectively). The ratios CSF NfHSMI35/CSF sAPPa,-ß were elevated in patients with fast
progression of disease (p = 0.002 each). CSF Progranulin decreased with ongoing disease (p = 0.04).
Conclusions: This study provides new CSF candidate markers associated with progression of disease in ALS. The data
suggest that a deficiency of cellular neuroprotective mechanisms (decrease of sAPP) is linked to progressive neuro-axonal
damage (increase of NfHSMI35) and to progression of disease.
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Introduction
Amyotrophic lateral sclerosis (ALS) is the most common form of
motor neuron disease characterized by progressive degeneration of
spinal and bulbar innervating motor neurons as well as the
pyramidal motor neurons [1]. Despite a uniformly fatal outcome,
ALS shows a wide range of survival times from a few months to
several decades [2]. So far, the pathological determinants of
disease progression in ALS remain poorly understood [3]. It is
expected that the discovery of sensitive biomarkers of disease
progression could be useful for the rapid identification of beneficial
drugs in clinical trials, as well as for the prompt exclusion of
ineffective ones [4]. Ideally, they could help to shorten clinical
trials and limit the need for large placebo-controlled groups [5]. So
far, several candidate biomarkers of disease progression have been
investigated, though none gained clinical relevance [6,7]. Cere-
brospinal fluid (CSF) is a promising source for biomarkers in ALS
since the CSF compartment is in close anatomical contact with the
brain interstitial fluid, and could reflect biochemical changes
related to the disease [8]. In a previous study on frontotemporal
lobar degeneration (FTLD) including a limited number of patients
with ALS [9], we analyzed soluble non-amyloidogenic fragments
of beta-amyloid precursor protein (APP), sAPPa and sAPPß which
were suggested to protect neurons from proteasomal stress [10].
Extending on our previous study, we obtained prospective clinical
data on a large cohort of patients with ALS in order to evaluate
whether CSF levels of sAPPa and sAPPß would distinguish clinical
subgroups of ALS, correlate with disability on clinical scales
[11,12] and would be of prognostic relevance. To evaluate a
possible association with neurodegeneration in vivo the analyses
included an established marker for neuro-axonal damage, the
phosphorylated neurofilament heavy chain NfHSMI35 [13,14]. We
also analyzed the secreted growth factor Progranulin which was
shown to mediate proteolytic cleavage of TAR DNA binding
protein of 43 kDa (TDP-43) to evaluate a possible link to the
formation of phosphorylated and ubiquitinated aggregates [15].
Materials and Methods
Patients and controls
Paired CSF and serum samples were collected of 68 patients
with definite sporadic ALS according to revised EL Escorial
criteria [16] (Table 1) in a cross-sectional study between January
2008 and September 2009 by the Department of Neurology,
University of Ulm (Germany). Clinical follow-up data were
collected over a time of 6 months. The disease presented as
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extremity-onset ALS in 49 patients and as bulbar-onset in 19 in
patients. Motor function was quantified clinically using the
Medical Research Council grading system (MRCS) with the best
score being 60 (full power), testing the patients power on a scale
from 0 (no contraction) to 5 (full power) for shoulder abduction,
arm flexion, wrist extension, hip flexion, knee extension and ankle
dorsiflexion bilaterally [12]. Disability was rated using the revised
Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS-
R) [11] by two experienced neurologists in our department (CH
and AL), each unaware of the biomarker data. At time of lumbar
puncture, 61% of patients were treated with Riluzole (50 mg twice
a day). Disease progression was evaluated according to the
monthly change on the MRCS between baseline and follow-up as
previously described (DMRCS) [7]. The median was taken as cut-
off for statistical purposes. The top 50% were classified as rapidly
progressive and the bottom 50% as slowly progressive.
The control group consisted of 40 age-matched patients who
presented with infrequent episodic tension-type headache [17] and
showed no evidence of a structural, hemorrhagic or inflammatory
lesion in magnetic resonance imaging (MRI) of the brain. As
neurodegenerative disease controls, we included 20 patients with
idiopathic Parkinson’s disease (PD) [18] (median Hoehn and Yahr)
[19] 3, range 1–4) (Table 1). Paired aliquots of 1 ml CSF and
serum were stored in polypropylene tubes at 280uC until analysis.
Ethics statement
Written informed consent was obtained from all patients in
accordance with the Declaration of Helsinki, and the study was
approved by the ethics committee of the University of Ulm,
Germany.
sAPPa and sAPPß
For determination of sAPPa and sAPPß a multiplex enzyme-
linked immunosorbent assay technique based on electrochemolu-
minescence was applied (Meso Scale Discovery, MSD, Gaithers-
burg, Maryland, USA) according to the manufacturer’s protocols
[9]. Analysis plates precoated with 6E10 (Signet Covance,
Dedham, MA, USA) as capturing antibody for sAPPa, and
ANGU raised against amino acids 591–596 of APP695 [20] as
capturing antibody for sAPPß, were blocked and then subjected to
30 ml native CSF or recombinant sAPP dilution series as protein
standard. After washing, bound sAPP was detected by P2–1
antibody binding to the APP N-terminal domain [21]. Excess
antibody was removed, read buffer was added for 10 min and
plates were imaged using a Sector Imager 2400 (MSD,
Gaithersburg, USA). Lower limit of detection (LLOD =3 SD
above the blank signal) for sAPPa was 120 pg/ml, and 52 pg/ml
for sAPPß. All samples were measured in duplicates. Detailed
information on the analytical performance of this assay and
stability of sAPP under storage is provided by a previous study
[22].
NfHSMI35
A highly sensitive immunoassay developed in-house for
NfHSMI35 was used for quantification of NfH in CSF [23]. Briefly,
96-well plates (Multi-ArrayH plates, Meso Scale Discovery,
Gaithersburg, MD) were coated with the capture monoclonal
antibody SMI 35R (Covance, Emeryville, CA). Samples were
diluted 1:1 with TBS containing 1% BSA, 0.1% Tween 20 and
50 mM Barbitone (Sigma-Aldrich, Saint Louis, MO). After
washing, the secondary polyclonal rabbit anti-NfH antibody
(Sigma-Aldrich, Saint Louis, MO) was added to each well.
Subsequently the plates were incubated with polyclonal Sulfo-
TAG labelled goat anti-rabbit antibody (ruthenylated) (MSD,
Gaithersburg, MD), ECL read buffer (MSD) diluted 1:2 with
distilled water and the ECL signals were measured using the MSD
Sector Imager 2400 plate reader. A four-parameter weighted
logistic fit curve was generated, and sample concentrations
extrapolated and analysed using the Discovery Workbench 3.0
software (MSD). In this paper we adhere to a previously proposed
nomenclature [24] and indicate the capture antibodies used for
NfH phosphoform quantification in superscript NfHSMI35. Puri-
fied bovine NfH was obtained from US Biological (United States
Biological, Swampscott, MA). Standards ranged from 0 to
2500 pg/ml, and the sensitivity of the assay (background plus
three standard deviations) is 2.4 pg/ml, with an intra- and inter-
assay coefficient of variation of 4.8% and 8.4%. The standards
were stored at 220uC. All samples were measured in duplicates.
Progranulin
Levels of Progranulin in CSF and serum were determined using
ELISA according to the instructions as supplied by the
Table 1. Demographic data and basic CSF findings of patients included in this study.
ALS PD CTRL S
Fast Slow
n (female/male) 68 (30/38) 34 (16/18) 34 (14/20) 20 (10/10) 40 (20/20)
Median (Range)
Age 65 (33–84) 67 (33–84) 63 (39–74) 69 (44–86) 62 (21–71) NS
Duration of disease [months] 15 (6–67) 18 (6–67) 16 (6–58) 72 (6–300) NS*
MRCS 56 (33–60) 54 (40–60) 58 (38–60)
DMRCS 0.9 (0–9) 2 (0.9–9) 0.2 (0–0.9)
ALSFRS–R 40 (6–48) 41 (6–46) 40 (21–48)
CSF cell count [cells/mL] 1 (0–4) 1 (0–4) 1 (0–4) 1 (0–2) 1 (0–4) NS
Qalb (x 0.001) 6.4 (2.3–14.2) 6.6 (2.3–12.4) 5.5 (2.9–14.2) 6.0 (2.8–16.5) 5.4 (2.7–10.6) NS
*across subgroups of ALS.
ALSFRS-R = revised Amyotrophic Lateral Sclerosis Functional Rating Scale, CTRL = controls, fast = ALS patients with fast progression of disease over follow-up, MRCS
= Medical Research Council Sumscore, DMRCS = change in MRC score/time, NS = not significant, PD = Parkinson’s disease, Qalb = albumin CSF/serum quotient, slow
= ALS patients with slow progression of disease over follow-up, S = Significance in Kruskal-Wallis One Way Analysis of Variance on Ranks.
doi:10.1371/journal.pone.0023600.t001
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manufacturer (Human Progranulin ELISA Kit, AdipoGen Inc.,
Seoul, Korea). The accuracy of the ELISA was assessed by
‘‘Spike-and-recovery’’ and ‘‘linearity-of-dilution’’ experiments.
The serum samples were diluted 1:600, the CSF samples 1:12.
The sensitivity of the assay (background plus three standard
deviations) was 32 pg/ml. All samples were measured in
duplicates.
Statistical analysis
Data analysis was performed using SPSS (Version 17.0 SPSS
Inc., Chicago, IL, USA). Because of non-normal data distribution
(Kolmogorov-Smirnov test), the medians and interquartile ranges
are shown. Differences between two groups were compared using
Mann-Whitney Rank Sum Test. To compare raw data of multiple
groups, Kruskal-Wallis analysis of variance on ranks was applied,
followed in case of significance by Dunn’s Method. All correlations
were studied using Spearman’s rank correlation coefficient.
Multiple correlations were corrected using the Bonferroni method.
Receiver operating characteristic (ROC) analysis was used to
compare the sensitivity and specificity of the ratios CSF
NfHSMI35/CSF sAPPa and CSF NfHSMI35/CSF sAPPßa for
identification of ALS patients with a rapid progression of disease.
The Youden index was calculated to find the cut-off values which
maximize discriminating accuracy of the tests [25]. P-values,0.05
were considered significant.
Results
Clinical findings over follow-up
Motor function as measured by the MRCS decreased from a
median 56 (range 33–60) points at onset of study to a median 49
(range 7–60) points after 6 months. The median disease
progression on the MRCS was 0.92 in this cohort. The
ALSFRS-R decreased from a median 40 (range 6–48) points at
onset of study to a median of 35 (range 6–46) points after 6
months.
CSF cytology and albumin
No significant difference of the CSF cytology was observed
between patients with ALS and controls (Table 1). A mild blood-
CSF barrier dysfunction reflected by an elevated Qalb was
observed in 17% of patients with ALS.
sAPPa and sAPPß
Both CSF sAPPa and CSF sAPPß concentrations were decreased
in a subgroup of ALS patients with a rapid-progressive course of
disease (p= 0.03, and p=0.02, Figure 1). For all ALS patients
combined, no significant difference of CSF sAPPa and CSF sAPPß
concentrations to controls and PD was observed (p= 0.45, and
p=0.35). Both CSF sAPPa and sAPPß decreased as motor function
was progressively lost (change of MRC score/time) (R=20.3,
p= 0.04 for sAPPa, R=20.3, p= 0.01 for sAPPß). Both sAPPa and
sAPPß were decreased in patients with extremity onset of disease as
compared to patients with bulbar onset (p= 0.04, p= 0.02). No
difference of CSF sAPPa or sAPPß between ALS patients with and
without Riluzole was observed (p=0.54, p= 0.61). CSF sAPPa was
lower as disease duration increased (R=20.39, p= 0.01, Figure 2).
Similarly, sAPPß was lower as disease duration increased
(R=20.37, p= 0.01, Figure 2). There was a strong correlation of
CSF sAPPa with CSF sAPPß levels (R=0.89, p,0.001). For
neither sAPPa nor sAPPß a correlation between CSF and serum
levels was observed (p= 0.57, p= 0.15, respectively). No correlation
of sAPPa or sAPPß with clinical scores (MRCS or ALSFRS-R) at
time of lumbar puncture was observed (data not shown). Neither
CSF sAPPa nor sAPPß correlated with blood-CSF barrier function
as measured by Qalb (p= 0.1, and p=0.09). Furthermore, no
correlation of CSF sAPPa or CSF sAPPß with age of patients was
detectable (p= 0.6, and p=0.2).
Figure 1. CSF sAPPa/ß in ALS and controls. Box and dot plots show (A) CSF sAPPa and (B) CSF sAPPß in ALS, Parkinson’s disease (PD), and
controls (CTRL) as well as (C) ratio CSF NfHSMI35/CSF sAPPa and (D) ratio CSF NfHSMI35/CSF sAPPß (right side). ALS fast = patients with rapid
progression of disease over follow-up of 6 months, ALS slow = patients with slow progression of disease over follow-up. The box represents the 25th
to 75th quartile, the whiskers represent the range, and the horizontal line in the box represents the median.
doi:10.1371/journal.pone.0023600.g001
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NfHSMI35 and ratio NfHSMI35 to sAPPa, sAPPß
CSF NfHSMI35 was higher in patients with ALS as compared to
PD and controls (p,0.05 each, Figure 3). Furthermore, CSF
NfHSMI3 was elevated in the subgroup of patients with a rapid
progression of disease (p = 0.01, Table 2). There was no corre-
lation of CSF NfHSMI35 levels with either age (p = 0.7), disease
duration (p = 0.09) or blood-CSF barrier function (p = 0.52). No
difference of CSF NfHSMI3 between patients with bulbar and
extremity-onset (p = 0.62) or with and without riluzole was
detectable (p = 0.42). CSF NfHSMI3 decreased with increasing
CSF sAPPa and sAPPß concentrations (p = 0.001, R=20.42 for
sAPPa, and p= 0.007, R=20.35 for sAPPß, Figure 2). This
correlation was also observed in the subgroup of patients with a
rapid progression of disease (p = 0.01, R=20.45 for sAPPa, and
p= 0.04, R=20.38 for sAPPß).
We observed a difference of the ratio CSF NfHSMI35/CSF
sAPPa between ALS patients with fast progression of disease and a
slower progression of disease during the prospective follow-up
period (p = 0.002, Figure 1). Similarly, we observed a difference of
the ratio CSF NfHSMI35/CSF sAPPß between ALS patients with
fast progression of disease and a slower progression of disease over
follow-up (p= 0.002).
ROC-Analysis
Using ROC analysis, we determined a ratio CSF NfHSMI35/
CSF sAPPa of 2.1 (AUROCC 0.75, sensitivity 0.84, specificity
0.60, Youden index 0.43) and a ratio CSF NfHSMI35/CSF sAPPß
of 4.3 (AUROCC 0.74, sensitivity 0.83, specificity 0.59, Youden
index 0.41) as optimal cut-off to differentiate patients with a fast
progression of disease from patients with a slower progression of
disease.
For NfHSMI35, ROC analysis yielded a cut-off of 55.8 pg/ml
(AUROCC 0.7, sensitivity 0.8, specificity 0.57, Youden index
0.37), for CSF sAPPa a cut-off of 27.5 ng/ml (AUROCC 0.66,
sensitivity 0.53, specificity 0.74, Youden index 0.25), and for
sAPPß a cut-off of 29.5 ng/ml (AUROCC 0.67, sensitivity 0.82,
specificity 0.5, Youden index 0.32) to differentiate patients with a
fast progression of disease from patients with a slower progression
of disease.
Progranulin
We observed no difference of either CSF or serum Progranulin
concentrations between patients with ALS, PD and controls
(p = 0.8, and p=0.4). Similarly, there was no difference of CSF
Figure 2. CSF sAPPa/ß in relation to disease progression and NfH. Upper diagrams: Dot plot shows CSF sAPPa and sAPPß in patients with
ALS plotted against duration of disease. Straight line represents regression line; correlation was significant (R =20.39, p = 0.01 for sAPPa and
R =20.37, p = 0.01 for sAPPß). Lower diagrams: Dot plot shows CSF sAPPa and sAPPß in patients with ALS plotted against NfHSMI35. Straight line
represents regression line; correlation was significant (p = 0.001, R =20.42 for sAPPa, and p= 0.007, R =20.35 for sAPPß).
doi:10.1371/journal.pone.0023600.g002
Figure 3. CSF NfH in ALS and controls. Box and dot plots show CSF
NfHSMI35 in ALS, Parkinson’s disease (PD), and controls (CTRL). ALS fast
= patients with rapid progression of disease over follow-up of 6
months, ALS slow = patients with slow progression of disease over
follow-up. The box represents the 25th to 75th quartile, the whiskers
represent the range, and the horizontal line in the box represents the
median. Difference between the groups was significant (p,0.001,
Kruskal-Wallis Analysis of Variance on Ranks), with post-hoc analysis
(Dunn’s method) showing patients with ALS to have significantly higher
CSF concentrations as compared to patients with PD and controls
(p,0.05 each).
doi:10.1371/journal.pone.0023600.g003
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Progranulin between subgroups of ALS patients with fast and slow
disease progression (p= 0.07). Likewise there was no difference of
CSF Progranulin between patients with bulbar or extremity-onset
(p = 0.67) or treatment with Riluzole (p = 0.17). We observed no
correlation of CSF Progranulin with age of patients (p = 0.12). We
also found no correlation of CSF Progranulin with blood-CSF
barrier function as measured by Qalb (p = 0.9). We observed an
inverse correlation of CSF Progranulin levels with duration of
disease (p = 0.04, R=20.32). No correlation of serum levels with
duration of disease was detectable (p = 0.78).
Discussion
We observed CSF levels of sAPPa and sAPPß to be altered in
subgroups of ALS: They were a) decreased in patients with a
rapid-progressive course of disease over follow-up (Figure 1) and b)
in patients with extremity-onset of disease. Furthermore, both CSF
sAPPa and sAPPß were found to decrease with ongoing disease
(Figure 2). In accordance with previous observations, CSF sAPPa
and sAPPß concentrations were strongly correlated [9,22]. With
regard to the specificity of the assay used to determine sAPPa/ß, a
recent study revealed no significant cross-reactivity of antibodies
specific for sAPPa or sAPPß with other CSF proteins [22].
Cleavage of APP by the a-and ß-secretase pathway results in the
production of the sAPPa or sAPPß fragment [26]. As sAPPa and
sAPPß are mainly produced by neurons,[27] decrease of CSF
sAPP was suggested to reflect loss of functional neurons in
neurodegenerative disease [28]. Consequently, decreasing CSF
sAPPa and sAPPß with ongoing disease as detected in our study
could reflect progressing neuronal loss or dysfunction in ALS. The
mechanisms underlying low CSF sAPP in patients with extremity-
onset are so far unclear. No difference regarding the extent and
distribution of protein aggregates in the lower motor neuron
columns with regard to site of disease onset was observed [29]. We
speculate that lower CSF sAPP levels are related to the larger
number of neurons lost in extremity onset compared to bulbar
onset disease. Secreted APPa was suggested to have potent
neuroprotective capacities: It binds to a specific receptor linked to
cyclic-GMP (cGMP) production and activation of cGMP-depen-
dent protein kinase (PKG), promoting activation of the nuclear
transcription factor NF-kB; these effects of sAPPa are believed to
mediate its neuron-survival-promoting properties [30]. Further-
more, sAPPa was found to protect neurons from proteasomal
stress [31] by inhibiting the stress-triggered pro-apoptotic c-Jun N-
terminal kinase (JNK)-signaling pathway [10]. Impaired protea-
somal function is a major hallmark in the pathophysiology of
neurodegenerative diseases, and it may explain the increased
ubiquitination and presence of proteinaceous aggregates such as
Nf in ALS [32]. Consequently, low CSF sAPPa concentrations
observed in patients with a rapid-progressive course of disease
could mirror a deficiency of neuronal mechanisms involved in
protein degradation and protection against misfolded or damaged
proteins in ALS. With decreased sAPP levels one may expect more
NfH aggregates to develop.
We found an inverse correlation of both sAPPa and sAPPß
levels with NfHSMI35 in the CSF (Figure 2). In a previous study, we
observed high concentrations of NfHSMI35 in ALS to mirror
extensive axonal damage and indicate a rapid progression of
disease [7]. In accordance with our previous study, we observed
NfHSMI35 to be elevated in the CSF of patients with ALS as
compared to all other groups (Figure 3), with highest concentra-
tions found in patients with a rapid-progressive course of disease
over follow-up. The inverse correlation of CSF sAPPa and sAPPß
with CSF NfHSMI35 which was prominent in patients with a rapid
progression of disease suggests that low CSF concentrations of
sAPP in ALS are linked to extensive neuro-axonal damage. Our
data support the relevance of sAPPa and -ß as neuroprotective
agents and provides in vivo evidence that a deficiency of cellular
mechanisms protective against the formation of proteinaceous
aggregates could be a determinant of disease progression in ALS.
As both high CSF NfHSMI35 and low CSF sAPPa and -ß were
associated with a rapid deterioration of motor function over
Table 2. CSF and Serum sAPPa, sAPPß, NfHSMI35, and Progranulin (PRGN) in patients with ALS, Parkinson’s disease (PD), and
controls (CTRL).
ALS PD CTRL S
Fast Slow
Median (Range)
CSF sAPPa
[ng/ml]
24 (7–52) 21 (7–36) 28 (13–52) 27 (14–55) 28 (13–48) p = 0.03*
Ser sAPPa
[ng/ml]
285 (128–493) 310 (235–493) 278 (128–426) 294 (188–597) 334 (159–547) NS
CSF sAPPß
[ng/ml]
37 (7–79) 29 (7–56) 41 (19–79) 37 (20–75) 41 (22–65) p = 0.02*
Ser sAPPß
[ng/ml]
44 (15–310) 48 (29–310) 44 (15–63) 48 (19–82) 50 (24–121) NS
CSF NfHSMI35
[pg/ml]
67 (14–397) 108 (27–397) 52 (14–177) 18 (4–156) 15 (3–66) p,0.001{
CSF PRGN
[ng/ml]
3.9 (2.2–8.2) 4.2 (2.2–7.4) 3.5 (2.6–8.2) 4.1 (2.6–4.5) 4.3 (2.3–7.0) NS
Ser PRGN
[ng/ml]
105 (52–269) 123 (63–235) 98 (52–269) 110 (65–196) 109 (79–185) NS
{Comparison across all groups, Kruskal-Wallis Analysis of Variance on Ranks.
*Comparison of ALS fast vs. ALS slow, Mann-Whitney Rank Sum Test.
Fast = ALS patients with fast progression of disease over follow-up, slow = ALS patients with slow progression of disease over follow-up, S = statistical significance.
doi:10.1371/journal.pone.0023600.t002
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follow-up, we determined a combined analysis of those markers.
The ratios CSF NfHSMI35/CSF sAPPa and CSF NfHSMI35/CSF
sAPPß were superior to NfHSMI35 and sAPPa,ß alone to delineate
patients with a fast progression of disease and are therefore
promising candidate biomarkers of disease progression for clinical
trials of ALS. In analogy to what has been proposed for combining
CSF tau and abeta levels in Alzheimer’s disease we propose
combining CSF NfH and sAPP in ALS. However, there was an
overlap between the groups and the number of patients included
was comparatively low, so the cut-offs determined here using
ROC-analysis will have to be validated on a large cohort of
patients with ALS. We propose this to be done in an unbiased,
staged multicenter, validation strategy.
Though no significant difference of CSF or serum Progranulin
between patients with ALS and controls was detectable, we
observed a tendency of CSF Progranulin to decrease with ongoing
disease. Progranulin mediates proteolytic cleavage of TDP-43 to
generate ,35 and ,25 kDa species [15]. Suppression of
Progranulin expression was shown to lead to caspase-dependent
accumulation of TDP-43 fragments [15]. Decreasing CSF
Progranulin levels with ongoing disease as observed in our study
could mirror deficient cleavage of TDP-43 and could contribute to
the formation of proteinaceous aggregates in ALS.
Our data provides indirect biomarker in vivo evidence that a
deficiency of neuroprotective mechanisms involved in protein
degradation and cleavage is linked to progressive neuro-axonal
damage in ALS. On a clinical level, this study provides new CSF
candidate markers associated with progression of disease in ALS.
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